Momenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL
February 17 2017 - 8:00AM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the termination of the applicable
waiting period under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976 (HSR Act) in connection with the collaboration and
license agreement with CSL to develop Fc multimer programs,
including M230, executed by the Company on January 5, 2017.
With the termination of the applicable waiting
period under the HSR Act, the collaboration and license agreement
with CSL is effective as of February 17, 2017. Under the license
agreement, CSL will pay Momenta a $50 million upfront cash payment
within 30 days of the effective date.
Additional details regarding the collaboration
can be found in Momenta’s Form 8-K filed with the Securities and
Exchange Commission on January 5, 2017.
About Momenta
Momenta Pharmaceuticals is a biotechnology
company specializing in the detailed structural analysis of complex
drugs and is headquartered in Cambridge, MA. Momenta is
applying its technology to the development of generic versions of
complex drugs, biosimilar and potentially interchangeable
biologics, and to the discovery and development of novel
therapeutics for autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does
not form a part of this press release.
Our logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
MOMENTA INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
MOMENTA MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2024 to May 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From May 2023 to May 2024